CN119219562A - 一种喹唑啉酮衍生物的制备方法 - Google Patents
一种喹唑啉酮衍生物的制备方法 Download PDFInfo
- Publication number
- CN119219562A CN119219562A CN202411102409.4A CN202411102409A CN119219562A CN 119219562 A CN119219562 A CN 119219562A CN 202411102409 A CN202411102409 A CN 202411102409A CN 119219562 A CN119219562 A CN 119219562A
- Authority
- CN
- China
- Prior art keywords
- reaction
- quinazolinone derivative
- derivative according
- potassium
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000003513 alkali Substances 0.000 claims abstract description 9
- FQGFFRUYSHLDDP-UHFFFAOYSA-N 2-(2-bromophenyl)-2,3-dihydro-1h-quinazolin-4-one Chemical compound BrC1=CC=CC=C1C1NC2=CC=CC=C2C(=O)N1 FQGFFRUYSHLDDP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000005695 dehalogenation reaction Methods 0.000 claims abstract description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 72
- 238000006243 chemical reaction Methods 0.000 claims description 59
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 19
- -1 amino, carboxyl Chemical group 0.000 claims description 18
- 239000012074 organic phase Substances 0.000 claims description 16
- 239000000741 silica gel Substances 0.000 claims description 14
- 229910002027 silica gel Inorganic materials 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000012298 atmosphere Substances 0.000 claims description 6
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000012300 argon atmosphere Substances 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 238000003818 flash chromatography Methods 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000004280 Sodium formate Substances 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000011056 potassium acetate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims description 2
- 235000019254 sodium formate Nutrition 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- 238000007256 debromination reaction Methods 0.000 abstract description 2
- 230000005595 deprotonation Effects 0.000 abstract description 2
- 238000010537 deprotonation reaction Methods 0.000 abstract description 2
- 230000027756 respiratory electron transport chain Effects 0.000 abstract description 2
- 238000009901 transfer hydrogenation reaction Methods 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 239000012043 crude product Substances 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 238000011068 loading method Methods 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 229920001971 elastomer Polymers 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 239000010453 quartz Substances 0.000 description 5
- 239000004576 sand Substances 0.000 description 5
- VDULOAUXSMYUMG-UHFFFAOYSA-N 2-phenyl-1h-quinazolin-4-one Chemical compound N=1C2=CC=CC=C2C(O)=NC=1C1=CC=CC=C1 VDULOAUXSMYUMG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010523 cascade reaction Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- UTEHUKGJDLVHIH-UHFFFAOYSA-N 2-(4-methylphenyl)-1h-quinazolin-4-one Chemical compound C1=CC(C)=CC=C1C1=NC(=O)C2=CC=CC=C2N1 UTEHUKGJDLVHIH-UHFFFAOYSA-N 0.000 description 2
- SVVNZCGMBNAQFW-UHFFFAOYSA-N 2-thiophen-2-yl-1h-quinazolin-4-one Chemical compound N1C2=CC=CC=C2C(=O)N=C1C1=CC=CS1 SVVNZCGMBNAQFW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- FSJSYDFBTIVUFD-SUKNRPLKSA-N (z)-4-hydroxypent-3-en-2-one;oxovanadium Chemical compound [V]=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O FSJSYDFBTIVUFD-SUKNRPLKSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- XWWYZFUBBJHKSP-UHFFFAOYSA-N 2,3-dihydro-1h-quinazolin-4-one Chemical compound C1=CC=C2C(=O)NCNC2=C1 XWWYZFUBBJHKSP-UHFFFAOYSA-N 0.000 description 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical class C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 1
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000011941 photocatalyst Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02B—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
- Y02B20/00—Energy efficient lighting technologies, e.g. halogen lamps or gas discharge lamps
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本申请提供了一种喹唑啉酮衍生物的制备方法,该方法包括以下步骤:碱催化下,2‑(2‑溴苯基)‑2,3‑二氢喹唑啉‑4(1H)‑酮进行脱卤加氢反应,得到喹唑啉酮类衍生物。该方法在碱的作用下NH基去质子化、电子转移后得到中间体,中间体得到质子随后进行质子转移加氢脱溴得到喹唑啉酮类衍生物,并且使用光、热两种方法均获得目标产物,原料合成简单,可有效降低生产成本、提高收率和化学选择性,可以便捷地应用于制备喹唑啉酮类衍生物。
Description
技术领域
本申请属于有机化合物合成技术领域,涉及一种喹唑啉酮衍生物的制备方法。
背景技术
喹唑啉酮骨架是一类具有潜在药理学和生物学活性的稠合杂环化合物。它们是天然产物、农用化学品、药物和合成药物中的基本单位(图1)。一种特殊类型的杂环框架,2,3-二氢喹唑啉-4(1H)-酮(DHQ),由于其强大的药理学和生物学作用,如抗癌、抗惊厥、镇痛、利尿、抗组胺和抗高血压活性,在各种药物中起着至关重要的作用。
目前报道的喹唑啉酮类化合物的合成方法主要有以下几种:
2013年,Dan Zhan课题组报道了在空气气氛下,以乙酰丙酮氧钒为催化剂,邻氨基苯甲酰胺和芳香醛串联反应合成2-取代和2,3-二取代喹唑啉-4(3H)-酮的方法。
2023年Peng Ma课题组本文报道了一种Cu(I)催化的以乙酰胺为氮源、H2O为氢源的环化/加氢脱卤级联反应合成喹唑啉类化合物的新方法。
2014年,Li-XiaWang,一种铜催化的方法,通过涉及C-C键裂解的多米诺反应合成2-芳基喹唑啉酮。该方案涉及分子内C-C键裂解以构建2-芳基喹唑啉酮,除了C-C键裂解外,该多米诺反应还包括N-芳基化和苄基C-H酰胺化。
2021年,Zongbo Xie课题首次报道在室温下以各种氨基苯甲酰胺和原位生成的醛为原料合成喹唑啉酮的简便串联路线。后者是通过C-C键裂解形成的,整个反应在没有光催化剂的情况下使用分子氧作为清洁氧化剂进行。可见光在整个反应过程中起着多重作用,可见光首先将苯乙烯裂解为醛,然后促进其与邻代苯胺的环化,最后促进环化中间体的脱氢反应。
发明内容
本发明实施例的目的在于提供一种喹唑啉酮衍生物的制备方法,旨在解决上述背景技术中提出的问题。
本发明实施例是这样实现的,一种喹唑啉酮衍生物的制备方法,包括以下步骤:碱催化下,2-(2-溴苯基)-2,3-二氢喹唑啉-4(1H)-酮进行脱卤加氢反应,得到喹唑啉酮类衍生物,反应式如下:
所述邻卤苯胺二氢喹啉的X基为氟、氯、溴、碘中的一种,L基为氧或硫;所述邻卤苯胺二氢喹啉喹唑啉酮类衍生物中R1、R2、R3、R4、R5、R6、R7和R8基各自独立地选自氢、卤素、取代或未取代的C1~10的烷基、取代或未取代的芳基、取代或未取代的C1~10烷氧基、取代或未取代的氨基、羧基、酯基、酰基、氰基、硝基、羟基、叠氮基中的一种。
优选地,所述碱邻卤苯基二氢喹啉的摩尔比1~2:1。
优选地,所述反应在溶剂存在下进行,所述溶剂为水、甲醇、乙醇、乙腈、苯、甲苯、四氢呋喃、1,4-二氧六环、二甲基亚砜、N,N-二甲基甲酰胺、乙二醇、聚乙二醇中的一种或多种;
所述碱包括但不仅限于氢氧化钠、氢氧化钾、氢氧化铯、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、甲酸钠、甲酸钾、乙酸钠、乙酸钾、叔丁醇钠、叔丁醇钾、磷酸钾、DBU中的一种或多种。
优选地,所述热反应过程所述反应温度为60~140℃,反应时间为1~24h。
优选地,所述光反应过程所述反应温度为10-40℃,反应时间为1-48h。
所述反应光源为白色LED 6000~6500k,所述光源的功率为1~20W。
优选地,所述反应在空气或惰性气氛下进行,所述惰性气氛为氮气气氛或氩气气氛。
优选地,所述反应结束后,将反应液采用乙酸乙酯进行萃取,利用有机相水洗多次并使用无水硫酸镁干燥,最后有机相浓缩通过快速色谱、C18硅胶柱得到喹唑啉酮衍生物。
优选地,所述浓缩采用常压蒸馏、减压蒸馏、旋转蒸发中的一种。
优选地,也可以利用柱层析纯化进行后处理,所述柱层析以200~300目硅胶为分离树脂,洗脱剂选择石油醚、正己烷、二氯甲烷、水、乙腈、甲醇、乙酸乙酯中的至少一种。
优选地,所述喹唑啉酮类衍生物结构式如下所示:
本发明实例提供的一种喹唑啉酮衍生物的制备方法,在碱的作用下NH基去质子化、电子转移后得到中间体,中间体得到质子随后进行质子转移加氢脱溴得到喹唑啉酮类衍生物,并且使用光、热两种方法均获得目标产物,原料合成简单,可有效降低生产成本、提高收率和化学选择性,可以便捷地应用于制备喹唑啉酮类衍生物。
附图说明
图1为本发明实施例1提供的化合物3a的核磁1HNMR谱图;
图2为本发明实施例1制备的化合物3a的核磁13CNMR碳谱图。
具体实施方式
为了使本申请的目的、技术方案及优点更加清楚明白,以下结合实施例,对本申请进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本申请,并不用于限定本申请。
本申请提供了一种喹唑啉酮衍生物的制备方法,其特征在于,包括以下步骤:在碱作用下,2-(2-卤苯基)-2,3-二氢喹唑啉-4(1H)-酮进行脱卤加氢反应,得喹唑啉酮类衍生物,反应式如下:
其中,所述的X基为氟、氯、溴、碘中的一种,L基为氧或硫。
所R1、R2、R3、R4、R5、R6、R7和R8基各自独立地选自氢、卤素、取代或未取代的C1~10的烷基、取代或未取代的芳基、取代或未取代的C1~10烷氧基、取代或未取代的氨基、羧基、酯基、酰基、氰基、硝基、羟基、叠氮基中的一种。
该所述热反应过程温度为60~140℃,反应时间为1~24h。所述光反应过程温度10~40℃,反应时间为1~48h。所述反应光源为白色LED 6000~6500k,所述光源的功率为1~20W,所述反应在空气或惰性气氛下进行,所述惰性气氛为氮气气氛或氩气气氛。
按照本发明,该反应在溶剂存在下进行,所述反应在溶剂存在下进行,所述溶剂为水、甲醇、乙醇、乙腈、苯、甲苯、四氢呋喃、1,4-二氧六环、二甲基亚砜、N,N-二甲基甲酰胺、乙二醇、聚乙二醇中的一种或多种。应当理解,在本发明的反应中,上述溶剂的用途仅仅用于溶解反应物,溶剂本身并不参与反应,因此,只要选择能够溶解反应物和催化剂的溶剂均可实现本申请上述反应,本发明具体实施方式中虽然仅仅给出了上述部分作为溶剂的实施例,本领域技术人员应当理解,实施例仅仅用以解释本发明给出的较佳的实施方案而已,并不用于限定本发明,本领域技术人员在实施例给出的启示下,也可以按照本发明给出的其他溶剂,得到本发明。
按照本发明,所述碱与2-(2-溴苯基)-2,3-二氢喹唑啉-4(1H)-酮的摩尔比1~2:1,应当理解,在本发明的反应中,只要存在上述催化剂、反应物的条件下,即可按照上述摩尔比发生上述反应,本领域技术人员应当理解,无论二茂铁硫酰胺和烯基硼酸按照何种比例添加,参加反应的碱与2-(2-溴苯基)-2,3-二氢喹唑啉-4(1H)-酮的摩尔比始终是特定的。
按照本发明,反应结束后,将反应液采用乙酸乙酯进行萃取,利用有机相水洗多次并使用无水硫酸镁干燥,最后有机相浓缩通过快速色谱、C18硅胶柱得到喹唑啉酮衍生物。
为了进一步理解本发明,下面结合实施例对本发明提供的方法进行详细说明,本发明的保护范围不受以下实施例的限制。
以下结合具体实施例对本申请的具体实现进行详细描述。
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
以下结合具体实施例对本发明的具体实现进行详细描述。
实施例1
一种喹唑啉酮衍生物(化合物2a)的制备方法,其结构和制备方法如下:
方法一:
具体步骤为:称取2-(2-溴苯基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,60mg),碳酸铯(0.2mmol,65.2mg)于25mL史莱克管中,加入DMF(2mL)塞好塞子,将其移入120℃的沙浴锅中并搅拌,反应过夜,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-苯基喹唑啉-4(3H)-酮,白色固体,分离收率79%。
方法二:
具体步骤为:称取2-(2-溴苯基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,60mg),叔丁醇钾(0.4mmol,44.8mg)于25mL石英管中,加入磁子,加入DMF(2mL)塞好橡胶塞,将其放置在室温,10W白色LED的照射下,将混合物搅拌12小时,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-苯基喹唑啉-4(3H)-酮,白色固体,分离收率84%。
化合物2a的结构鉴定:
核磁共振数据:
1H NMR(500MHz,DMSO-d6)δ12.52(s,1H),8.20(d,J=7.4Hz,2H),8.17(d,J=7.8Hz,1H),7.84(t,J=7.6Hz,1H),7.75(d,J=8.1Hz,1H),7.60–7.51(m,4H).
13C NMR(126MHz,DMSO-d6)δ162.86,152.95,149.19,135.00,133.32,131.81,129.05,128.24,127.87,126.98,126.33,121.47.
化合物2a的1HNMR、13CNMR数据分析结果表明,获得的目标产物正确。
实施例2
一种喹唑啉酮衍生物(化合物2a)的制备方法,其结构和制备方法如下:
方法一:
具体步骤为:称取2-(2-碘苯基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,70mg),碳酸铯(0.2mmol,65.2mg)于25mL史莱克管中,加入磁子,加入DMF(2mL)塞好塞子,将其移入120℃的沙浴锅中并搅拌,反应过夜,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-苯基喹唑啉-4(3H)-酮,白色固体,分离收率69%。
方法二:
具体步骤为:称取2-(2-碘苯基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,70mg),叔丁醇钾(0.4mmol,44.8mg)于25mL石英管中,加入磁子,加入DMF(2mL)塞好橡胶塞,在室温下10W白色LED的照射下,将混合物搅拌12小时,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-(5-甲基苯)喹唑啉-4(3H)-酮,白色固体,分离收率76%。
化合物2a的结构鉴定:
核磁共振数据:
1H NMR(500MHz,DMSO-d6)δ12.52(s,1H),8.20(d,J=7.4Hz,2H),8.17(d,J=7.8Hz,1H),7.84(t,J=7.6Hz,1H),7.75(d,J=8.1Hz,1H),7.60–7.51(m,4H).
13C NMR(126MHz,DMSO-d6)δ162.86,152.95,149.19,135.00,133.32,131.81,129.05,128.24,127.87,126.98,126.33,121.47.
化合物2ab的1H NMR、13C NMR数据分析结果表明,获得的目标产物正确。
实施例3
一种喹唑啉酮衍生物(化合物2e)的制备方法,其结构和制备方法如下:
方法一:
具体步骤为:称取2-(2-溴-4-甲基苯基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,63.2mg),碳酸铯(0.2mmol,65.2mg)于25mL史莱克管中,加入DMF(2mL)塞好塞子,将其移入120℃的沙浴锅中并搅拌,反应过夜,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-(对甲苯基)喹唑啉-4(3H)-酮,白色固体,分离收率72%。
方法二:
具体步骤为:称取2-(2-溴-4-甲基苯基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,63.2mg),叔丁醇钾(0.4mmol,44.8mg)于25mL石英管中,加入DMF(2mL)塞好橡胶塞,在室温下10W白色LED的照射下,将混合物搅拌12小时。用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-(对甲苯基)喹唑啉-4(3H)-酮,白色固体,分离收率81%。
化合物2e的结构鉴定:
核磁共振数据:
1H NMR(500MHz,DMSO-d6)δ12.46(s,1H),8.14(dd,J=8.0,J=1.5Hz,1H),8.11(d,J=8.0Hz,2H),7.85–7.80(m,1H),7.73(d,J=8.1Hz,1H),7.50(t,J=7.4Hz,1H),7.36(d,J=8.0Hz,2H),2.39(s,3H)
13C NMR(126MHz,DMSO-d6)δ163.04,152.99,149.30,141.83,134.92,130.58,129.63,128.16,127.74,126.74,126.31,121.37,21.45.
化合物3b的1H NMR、13C NMR数据分析结果表明,获得的目标产物正确。
实施例4
一喹唑啉酮衍生物(化合物2f)的制备方法,其结构和制备方法如下:
具体步骤为:称取2-(2-溴-4-甲氧基苯基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,66.6mg),碳酸铯(0.2mmol,65.2mg)于25mL史莱克管中,加入DMF(2mL)塞好塞子,将其移入120℃的沙浴锅中并搅拌,反应过夜,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-(对甲苯基)喹唑啉-4(3H)-酮,白色固体,分离收率57%。
方法二:
具体步骤为:称取2-(2-溴-4-甲基苯基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,66.2mg),叔丁醇钾(0.4mmol,44.8mg)于25mL石英管中,加入磁子,加入DMF(2mL)塞好橡胶塞,在室温下10W白色LED的照射下,将混合物搅拌12小时,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-苯基喹唑啉-4(3H)-酮,白色固体,分离收率66%。
化合物2f的结构鉴定:
核磁共振数据:
1H NMR(500MHz,DMSO-d6)δ12.39(s,1H),8.23–8.17(m,2H),8.13(dd,J=8.0,1.5Hz,1H),7.83–7.78(m,1H),7.71(d,J=8.1Hz,1H),7.51–7.44(m,1H),7.11–7.07(m,2H),3.85(s,3H).
13C NMR(126MHz,DMSO)δ162.34,134.96,129.95,126.55,126.29,125.37,121.12,114.47,55.95,40.90,40.49,40.33,40.16,39.99,39.83,39.66,39.49.
化合物2c的1H NMR、13C NMR数据分析结果表明,获得的目标产物正确。
实施例5
一种喹唑啉酮衍生物(化合物2h)的制备方法,其结构和制备方法如下:
方法一:
具体步骤为:称取2-(3-溴噻吩-2-基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,61.8mg),碳酸铯(0.2mmol,65.2mg)于25mL史莱克管中,加入磁子,加入DMF(2mL)塞好塞子,将其移入120℃的沙浴锅中并搅拌,反应过夜,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-(噻吩-2-基)喹唑啉-4(3H)-酮,白色固体,分离收率42%。
方法二:
具体步骤为:称取2-(3-溴噻吩-2-基)-2,3-二氢喹唑啉-4(1H)-酮(0.2mmol,61.8mg),叔丁醇钾(0.4mmol,44.8mg)于25mL石英管中,加入DMF(2mL)塞好橡胶塞,在室温下10W白色LED的照射下,将混合物搅拌12小时,用TLC检测跟踪反应,反应结束后,将反应管冷却至室温,向体系中加入10mL饱和食盐水,搅拌;用乙酸乙酯萃取(10mL×3),合并有机相,用旋转蒸发仪去除溶剂,得到粗产品;粗产品经过硅胶负载,洗脱剂采用体积比石油醚:乙酸乙酯=5:1进行柱层析纯化后,得纯品2-(噻吩-2-基)喹唑啉-4(3H)-酮,白色固体,分离收率39%。
化合物2n的结构鉴定:
核磁共振数据:
1H NMR(500MHz,DMSO-d6)δ12.56(s,1H),8.20(d,J=4Hz,1H),8.12(dd,J=8.0,1.5Hz,1H),7.85(d,J=5.0Hz,1H),7.81–7.75(m,1H),7.64(d,J=8.5Hz,1H),7.50–7.43(m,1H),7.26–7.21(m,1H).
13C NMR(126MHz,DMSO-d6)δ163.12,149.34,134.83,132.26,129.61,129.07,128.89,127.23,126.45,121.44.
化合物2h的1H NMR、13C NMR数据分析结果表明,获得的目标产物正确。
申请人还通过上述实施例1相似的方法合成了其他喹唑啉酮衍生物,区别在于反应原料、产物和产物收率不同,请参看表1。
表1喹唑啉酮衍生物合成情况表
最后应说明的是:以上实施例仅用以说明本申请的技术方案,而非对其限制;尽管参照前述实施例对本申请进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本申请实施例技术方案的范围。
Claims (8)
1.一种喹唑啉酮衍生物的制备方法,其特征在于,包括以下步骤:在碱作用下,2-(2-卤苯基)-2,3-二氢喹唑啉-4(1H)-酮进行脱卤加氢反应,得喹唑啉酮类衍生物,反应式如下:
所述的X基为氟、氯、溴、碘中的一种,L基为氧或硫;
所R1、R2、R3、R4、R5、R6、R7和R8基各自独立地选自氢、卤素、取代或未取代的C1~10的烷基、取代或未取代的芳基、取代或未取代的C1~10烷氧基、取代或未取代的氨基、羧基、酯基、酰基、氰基、硝基、羟基、叠氮基中的一种。
2.根据权利要求1所述喹唑啉酮衍生物的制备方法,其特征在于,所述碱与2-(2-溴苯基)-2,3-二氢喹唑啉-4(1H)-酮的摩尔比1~2:1。
3.根据权利要求1所述喹唑啉酮衍生物的制备方法,其特征在于,所述反应在溶剂存在下进行,所述溶剂为水、甲醇、乙醇、乙腈、苯、甲苯、四氢呋喃、1,4-二氧六环、二甲基亚砜、N,N-二甲基甲酰胺、乙二醇、聚乙二醇中的一种或多种;
所述碱为氢氧化钠、氢氧化钾、氢氧化铯、碳酸钠、碳酸钾、碳酸铯、碳酸氢钠、碳酸氢钾、甲酸钠、甲酸钾、乙酸钠、乙酸钾、叔丁醇钠、叔丁醇钾、磷酸钾、DBU中的一种或多种。
4.根据权利要求1所述喹唑啉酮衍生物的制备方法,其特征在于,所述热反应过程温度为60~140℃。
5.根据权利要求1所述喹唑啉酮衍生物的制备方法,其特征在于,所述光反应过程温度为室温。
6.根据权利要求5所述喹唑啉酮衍生物的制备方法,其特征在于,所述反应光源为白色LED 6000~6500k,所述光源的功率为1~20W。
7.根据权利要求1所述喹唑啉酮衍生物的制备方法,其特征在于,所述反应在空气或惰性气氛下进行,所述惰性气氛为氮气气氛或氩气气氛。
8.根据权利要求1所述的喹唑啉酮衍生物的制备方法,其特征在于,所述反应结束后,将反应液采用乙酸乙酯进行萃取,利用有机相水洗多次并使用无水硫酸镁干燥,最后有机相浓缩通过快速色谱、C18硅胶柱得到喹唑啉酮衍生物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411102409.4A CN119219562A (zh) | 2024-08-12 | 2024-08-12 | 一种喹唑啉酮衍生物的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411102409.4A CN119219562A (zh) | 2024-08-12 | 2024-08-12 | 一种喹唑啉酮衍生物的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119219562A true CN119219562A (zh) | 2024-12-31 |
Family
ID=93942691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411102409.4A Pending CN119219562A (zh) | 2024-08-12 | 2024-08-12 | 一种喹唑啉酮衍生物的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119219562A (zh) |
-
2024
- 2024-08-12 CN CN202411102409.4A patent/CN119219562A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cheng et al. | Intramolecular cross dehydrogenative coupling of 4-substituted coumarins: rapid and efficient access to coumestans and indole [3, 2-c] coumarins | |
| WO2023109968A2 (zh) | 非奈利酮及其中间体的合成方法 | |
| Guo et al. | One-pot three-component selective synthesis of isoindolo [2, 1-a] quinazoline derivatives via a palladium-catalyzed cascade cyclocondensation/cyclocarbonylation sequence | |
| CN114014805B (zh) | 三氟甲基化2,4-喹啉二酮类化合物的制备方法 | |
| Nguyen et al. | Copper-catalyzed synthesis of pyrido-fused quinazolinones from 2-aminoarylmethanols and isoquinolines or tetrahydroisoquinolines | |
| CN107540678B (zh) | 一种分子内交叉脱氢偶联制备香豆素并杂芳环类化合物及其衍生物的方法 | |
| CN117209437B (zh) | 一种胺基喹唑啉酮衍生物的制备方法 | |
| Zhang et al. | An improved synthesis of telmisartan via the copper-catalyzed cyclization of o-haloarylamidines | |
| Hostyn et al. | Highly efficient one-pot synthesis of D-ring chloro-substituted neocryptolepines via a condensation—Pd-catalyzed intramolecular direct arylation strategy | |
| CN119219562A (zh) | 一种喹唑啉酮衍生物的制备方法 | |
| CN114516808B (zh) | 一种氨基保护的苯并环酮类化合物的制备方法 | |
| CN113912609B (zh) | 一种天然生物碱色胺酮及其衍生物的制备方法 | |
| Hu et al. | A facile synthesis of 4-aryl-1, 2, 3, 4-tetrahydroisoquinolines | |
| CN114671867B (zh) | 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法 | |
| WO2009116089A2 (en) | Novel intermediates and method for synthesis of 4'-[(1,4'-dimethyl-2'-propyl-[2,6'- bi-1hbenzimidazol]-l-yl)methyl]-1,1-biphenyl]-2-carboxylic acid. | |
| Honnanayakanavar et al. | Tandem copper catalyzed regioselective N-arylation–amidation: synthesis of angularly fused dihydroimidazoquinazolinones and the anticancer agent TIC10/ONC201 | |
| CN111718301B (zh) | 一种喹唑啉酮衍生物的合成方法 | |
| CN111018795B (zh) | 一种碱性条件下合成喹喔啉-3-酮的方法 | |
| Yuan et al. | Photoredox-catalysed radical difluoromethylation/cyclization of N-acryloyl-2-arylbenzimidazole to access CF 2 H-substituted benzimidazo [2, 1-a] isoquinolin-6 (5 H)-ones | |
| Wang et al. | Synthesis of Chiral 2‐trifluoromethyl‐4‐(tetrahydroquinolinyl)‐4H‐chromenes via Pd‐Catalyzed Asymmetric Amination | |
| Odilov et al. | An efficient synthesis of the last step key intermediate for telmisartan via Pd-catalyzed carbonylative cyclization | |
| CN108129402B (zh) | 以二苯乙炔类化合物为原料合成2-苯基喹唑啉酮类化合物的方法 | |
| CN109265403B (zh) | 一种苯并咪唑及其衍生物的合成方法 | |
| CN119977871B (zh) | 1,2-二溴-6-叔丁基-9-(4-叔丁基苯基)-9h-咔唑及其合成方法 | |
| CN108033919B (zh) | 以苯乙烯类化合物为原料合成2-苯基喹唑啉酮类化合物的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |